Clinical Trial Update: Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating binimetinib and encorafenib for pancreatic cancer with BRAF V600E mutation was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-01-23